Published • loading... • Updated
Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of ...
- Simcere Zaiming announced that the first US patient has begun treatment in a Phase 1 trial at The Tisch Cancer Institute, assessing the safety and preliminary efficacy of SIM0500 in relapsed/refractory multiple myeloma patients.
- SIM0500 is a humanized trispecific antibody targeting GPRC5D, BCMA, and CD3, developed with Simcere Zaiming's proprietary platform.
- In April 2024, the FDA granted SIM0500 a Fast Track designation due to its potential in treating RRMM, emphasizing its promise as a cornerstone for future therapies.
- BCMA and GPRC5D-targeted therapies have shown significant promise in treating RRMM and are expected to play a key role in future treatments.
Insights by Ground AI
68 Articles
68 Articles
Fox 4 Kansas City+66 Reposted by 66 other sources
Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma
·Kansas City, United States
Read Full Article
Coverage Details
Total News Sources68
Leaning Left8Leaning Right4Center25Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 22%
C 67%
11%
Factuality
To view factuality data please Upgrade to Premium
